Patent details
LUC00357 Product Name: Sparsentan or a pharmaceutically acceptable salt thereof
Basic Information
- Publication number:
- LUC00357
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP171576978
- Legal Status:
- Pending & Published
- Application number:
- LUC00357
- First applicant's nationality:
- Procedural language:
- English
Marketing Authorization
- Marketing Authorization Number:
- EU/1/23/1788
- Marketing Authorization Type:
- Marketing Authorization Date:
- 23/04/2024
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 25/09/2024
- First Marketing Authorization date:
- 23/04/2024
- Grant date:
- Activation date:
- Publication date:
- 26/09/2024
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 29/03/2035
- SPC Extension Expiration:
- 29/03/2035
- Rejection date:
- Withdrawal date:
Owner
- From:
- 25/09/2024
- Name:
- Ligand Pharmaceuticals Inc.
- Address:
- 3911 Sorrento Valley Boulevard Suite 110, San Diego, CA 92121, United States (US)
Agent
- Name:
- Dennemeyer & Associates S.A.
- From:
- 25/09/2024
- Address:
- 55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2024/12
- Publication date:
- 01/10/2024
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 01/04/2030
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 25/09/2024 | Application Form | 5 |
| 25/09/2024 | Marketing authorization | 4 |
| 25/09/2024 | Summary of the product caracteristics | 38 |
| 25/09/2024 | General Document | 1 |
| 25/09/2024 | MA publication | 1 |
| 25/09/2024 | Marketing authorization | 3 |
| 26/09/2024 | Publication | 1 |
| 26/09/2024 | Outgoing Correspondence | 1 |